Phase 2 acmopatide results in type 1 diabetes show promising weight loss and reduced insulin use. Explore A1C findings, safety, and limitations.
Read More »Retatrutide vs. Ozempic: What the 80-Week Head-to-Head Diabetes Trial Revealed
See how retatrutide compared with Ozempic 2 mg in an 80-week Phase 3 diabetes trial, including A1C reduction, weight loss, and side effects.
Read More »The Guidelines Moved Faster Than Prescribing Did
Explore why diabetes prescribing still lags behind clinical guidelines, despite growing evidence supporting SGLT2 inhibitors and GLP-1 therapies.
Read More »378 Trials, 113,000+ Participants: What Actually Works to Stop Prediabetes From Becoming Diabetes?
Discover what 378 trials involving 113,000+ participants reveal about prediabetes treatment, lifestyle changes, metformin, and incretin therapies.
Read More »GLP-1s and Opioids: The GI Risk Clinicians May Be Missing
GLP-1 receptor agonists have transformed the treatment of type 2 diabetes, but their effects on gastrointestinal motility remain an important clinical consideration. Opioids can also slow gastrointestinal function, raising an obvious question: what happens when patients need both? New research examining GLP-1 and opioid interactions suggests that opioid choice may …
Read More »GLP-1s and Vision Loss: What Prescribers Should Know About the Emerging NAION Signal
GLP-1 receptor agonists have transformed type 2 diabetes and obesity treatment, but a rare vision safety signal deserves clinicians’ attention. Emerging evidence has raised concerns about a potential NAION risk with GLP-1 therapy, particularly with semaglutide (Ozempic, Rybelsus, and Wegovy). Non-arteritic anterior ischemic optic neuropathy (NAION) can cause sudden, usually …
Read More »Could a Stool Test Predict Your Patient’s Best Diabetes Medication?
Could a stool sample someday help clinicians choose a diabetes medication before writing the prescription? Emerging research into gut biomarkers in diabetes is moving that possibility closer to clinical reality. Rather than simply cataloging which bacteria live in the intestine, researchers are examining microbial genes, stool-derived metabolites, and functional signatures …
Read More »The Glucagon Paradox: Why Activating a “Blood Sugar Hormone” Can Improve Metabolic Health
For decades, glucagon has been viewed as insulin’s opposite. While insulin lowers blood glucose, glucagon raises it by signaling the liver to release stored sugar into the bloodstream. Because of this, glucagon has traditionally been considered a hormone to suppress in people living with type 2 diabetes. However, modern research …
Read More »Protecting Muscle While Treating Obesity: New Protein Targets for Older Adults on GLP-1s
The rise of highly effective GLP-1 receptor agonists and dual incretin therapies has transformed obesity treatment. Medications such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are helping patients achieve levels of weight loss that were previously difficult to attain without bariatric surgery. However, as clinicians celebrate these advances, a …
Read More »Why Early Combination Therapy Is Gaining Momentum in Young-Onset Type 2 Diabetes
Young adults diagnosed with type 2 diabetes early in life often face a more aggressive disease course than older adults. While metformin has long served as the standard first-line therapy, many clinicians are now reconsidering whether a “metformin-first and wait” strategy is enough for this higher-risk population. As research continues …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.